Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN Study
Journal of Clinical Oncology - United States
doi 10.1200/jco.2017.76.8853
Full Text
Open PDFAbstract
Available in full text
Date
August 10, 2018
Authors
Publisher
American Society of Clinical Oncology (ASCO)